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unlikely. Some bias due to above average socio-economic status
of the insured population cannot be excluded.
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FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES
AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
Mullins CD, Kuznik A
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To describe factors which are associated with vari-
ations in the prescribed average daily dose of ziprasidone for the
treatment of schizophrenia. METHODS: We identiﬁed continu-
ously enrolled patients with a diagnosis of schizophrenia (ICD-
9 code 295.xx) between January 2001 and June 2003 from
Maryland Medicaid. The average daily dose prescribed was
deﬁned as the total amount dispensed divided by the days of
therapy. The effect of socio-demographic factors, recent hospi-
talization, psychiatric co-morbidities, and concurrent psychiatric
medication on the average daily dose prescribed was estimated
using ordinary least squares (OLS) regression. RESULTS: In the
sample of 1197 patients who met the inclusion criteria, the mean
average dose prescribed was 92mg per day (S.D.: 50mg). Males
were prescribed an 8mg higher average daily dose as compared
to females (p = 0.007). African Americans were prescribed 9mg
less as compared to Caucasians (p = 0.005). The average daily
dose prescribed increased if the patient was concurrently treated
with antidepressants by 8mg (p = 0.018), with antipsychotics by
16mg (p < 0.001), and with anticonvulsants by 12mg (p =
0.001). Patients who had a psychiatric hospitalization during the
30 days prior to initiation of therapy were prescribed average
daily doses that were 8mg higher, but this increase was not sta-
tistically signiﬁcant (p = 0.055). Patient age, the number of psy-
chiatric co-morbidities, and concurrent treatment with antimanic
and antianxiety medication were not found to statistically affect
prescribing patterns. CONCLUSION: Schizophrenia patients’
gender, race, and concurrent treatment medication signiﬁcantly
affect the decision makers prescribing patterns of ziprasidone in
terms of the average daily dose.
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OBJECTIVES: To evaluate 6-month clinical and economic out-
comes following initiation of long-acting injectable risperidone
(LAIR) in patients with schizophrenia/schizoaffective disorder.
METHODS: Data are collected via a secured web-based system,
retrospectively for 12-months and prospectively for 2-years.
Patient demographics, treatment and hospitalisation history,
reason for initiating new treatment, Clinical Global Impres-
sion—Severity (CGI-S), Global Assessment of Functioning (GAF)
and adverse event data are collected. This interim analysis
includes the ﬁrst 991 patients in Germany with at least 6 months
follow-up or who discontinued treatment during this 6 month
period. RESULTS: Of the 991 patients, 56% were male. Mean
age was 43 (±14) years, mean duration of illness at initiation of
LAIR was 10 (±10) years. A total of 79% were diagnosed with
schizophrenia whilst 17% had schizoaffective disorder. After 6-
months, 75% of patients still received their original starting
dose. Compared with the preceding 6-month period, fewer
patients required full hospitalisations (34% vs. 20%; p < 0.001).
Decreases from baseline were seen in the concomitant use of anti-
cholinergics (13.3% to 6.1%), antidepressants (18.1% to
11.8%), mood stabilisers (9.8% to 7.1%), benzodiazepines
(17.3% to 8.4%), and somatic medication (14.7% to 8.5%; all
comparisons p < 0.001). Compared to baseline, CGI-S ratings
improved from 4.7 to 3.8, and patient functioning (GAF)
increased from 46.7 to 58.0 at 6-months (both p < 0.001); 13%
of patients discontinued treatment with LAIR. Most frequent
reason (3.5%) was patient/family choice; 1.2% discontinued due
to adverse event. CONCLUSIONS: The 6-month interim data
show that the majority of patients initiated on LAIR remained
on stable doses. Discontinuation rates were low. Need for inpa-
tient care was reduced, as was use of psychotropic and somatic
concomitant medication. There was signiﬁcant and clinically rel-
evant improvement in illness and functioning. Longer term data
with larger sample size are being accrued to further explore these
outcomes over time.
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OBJECTIVES: From a longitudinal study, we observed the socio-
economic proﬁle and the occupational situation of a cohort of
schizophrenic patients over 1 year and we made an estimate of
the indirect costs in this population. METHODS: Occupations,
sources of income, health care and social situation were reported
regularly over a 1-year period by a group of 538 schizophrenic
outpatients. We speciﬁcally studied the population already inte-
grated into the workplace. Number and duration of work
absences were basic data for the calculation of indirect costs. In
this subgroup, we adopted the perspective of the Sickness Fund
(SF). The costing was performed by combining number and
duration of work absences, patient income levels in 2002, annual
number of workdays, SF rules for the coverage of workdays lost.
RESULTS: In our sample of 538 schizophrenic patients, 2% were
managers, 15% were white-collars, 5% were blue-collars, 8%
were unemployed and the rest of the population (70%) lived
without occupations or in occupation-aided structure. Work
absences occurred in 54% of managers with a median duration
of 184 days; this rate is at 36% for white-collars with a median
duration of 83 days; this rate is at 19% for blue-collars with a
median duration of 30 days. The median costs over 1-year due
to absenteeism at work were €7419, €3071, and €1100 for man-
agers, white-collars and blue-collars respectively. CONCLU-
SIONS: More than a quarter of our sample was employed and
integrated into society. We found that managers seemed to gen-
erate highest work absences in terms of number, duration and
costs; the position of managers and the level of related-stress
might have an impact on the natural course of the disease.
According to our ﬁndings, it is reasonable to estimate the indi-
rect costs of schizophrenia more accurately in the future.
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The last observation carried forward (LOCF) analysis overlooks
the meaningfulness of dropout in clinical trials. For antipsychotic
medication dropout is an important outcome since long-term
treatment is often required and dropout may relate to lack of
drug tolerability. OBJECTIVE: The current analysis applies the
“pattern mixture” approach (Shih & Quan, 1997) in which a
composite hypothesis is tested that consists of the probability
that there is a difference in completion rates (d) between two
drugs and the probability that there is a difference in efﬁcacy 
of complete cases (e) [p = p(d) ¥ p(e) ¥ (1- ln(p(d) ¥ p(e)].
METHODS: The pattern-mixture approach was applied to data
from a 53-week randomized, open-label non-inferiority efﬁcacy
trial of risperidone long-acting injectable (RLAI) vs. olanzapine
tablets (OLA) in treating schizophrenia (n = 618) (data on ﬁle
JNJ). RESULTS: LOCF had found a signiﬁcant difference (p =
0.04) on percent of patients in each group who attained clinical
improvement (20% improvement on PANSS total) favoring
RLAI and no signiﬁcance on difference in the continuous
measure of change in PANSS total (p = 0.83). Among completers
there was a greater decline on change in PANSS total favoring
RLAI (Ris -23.6(±14.4); Ola -21.9 (±18.0); 1-tailed p = 0.105).
76% of the RLAI treated patients completed the trial as com-
pared to 70% of the OLA treated patients (one-tailed p = 0.087).
Using the pattern mixture approach the probability for the com-
bined hypothesis of a difference in efﬁcacy in complete cases, and
trial completion, was signiﬁcant (p = 0.05). On clinical improve-
ment, 66.1% of RLAI group both completed the trial and
improved as compared to 53.7% of the olanzapine group (Odds
Ratio [95% Conﬁdence interval]: 1.84 [1.20 :2.82]). CONCLU-
SIONS: LOCF may not capture real-life, clinically important dif-
ferences which can be captured by other approaches.
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OBJECTIVES: This study quantiﬁes excess annual costs associ-
ated with schizophrenia patients in the United States in 2002
from a societal perspective. METHODS: Annual direct medical
costs associated with schizophrenia were estimated separately for
privately (n = 1090) and publicly (Medicaid n = 14,074) insured
patients based on administrative claims data, including a large
private claims database and a State Medicaid database, and com-
pared separately to demographically-geographically matched
control samples (1 case: 3 controls). Medicare costs were
imputed using the Medicare/Medi-Cal dual eligible patients (n =
1491) and published statistics. Excess annual direct non-health
care costs were estimated for law enforcement, homeless shel-
ters, and research/training related to schizophrenia. Excess
annual indirect costs were estimated for four components of pro-
ductivity loss: unemployment, reduced work place productivity,
premature mortality from suicide, and family care giving using
a human capital approach based on market wages. All costs were
adjusted to 2002 dollars using the Consumer Price Index and
were based on the reported prevalence in the National Comor-
bidity Survey Replication. RESULTS: The overall US 2002 cost
of schizophrenia was estimated to be $62.7 billion, with $22.7
billion excess direct health care cost ($7.0 billion outpatient,
$5.0 billion drugs, $2.7 billion inpatient, $8.0 billion long term
care). The total direct non-health care excess costs, including
living cost offsets, were estimated to be $7.6 billion. The total
indirect excess costs were estimated to be $32.4 billion. CON-
CLUSION: Schizophrenia is a debilitating illness resulting in sig-
niﬁcant costs. The indirect excess cost due to unemployment is
the largest component of overall schizophrenia excess annual
costs.
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The prevalence of schizophrenia varies between 0.2–1% and the
cost to treat patients is substantial. Modeling a schizophrenic
population is demanding since schizophrenia is a life long disease
during which patients go through many states and the transition
from one state to another is dependent on the history of patients.
A previously built 1st order Monte Carlo DES model was
adapted to enable 2nd order Monte Carlo simulation. OBJEC-
TIVE: This abstract describes why and how the model was
upgraded from a 1st order Monte Carlo (MC) simulation to a
2nd order MC model. The abstract will describe the choices
made in the design of the model, the internal validity and eval-
uation of its strengths and weaknesses. METHODS: Internal
validity of the model has been explored using data from several
patient databases, as well as literature on a list of variables,
including PANSS, the proportion of patients institutionalized
and costs. Pert, beta, lognormal and uniform distributions have
been used to describe 2nd order uncertainty of relevant variables,
such as PANSS, QALY, risk and costs. RESULTS: The model was
programmed to reﬂect the PANSS at 0 year, 1 year, and 5 years
for patients from the considered databases. The modeled annual
cost per patient and the location distribution were similar to pub-
lished data. Outcomes were expressed in terms of direct medical
costs, number and duration of episodes, PANSS, QALY, GAF,
CGI, SF36 and the SF6 mental component. The uncertainty sur-
rounding the outcomes of costs and effect measures were
assessed with acceptability curves and ellipses. DISCUSSION:
The original DES model was vastly improved with the use of
additional database analyses, additional correlation analyses and
2nd order Monte Carlo simulations. This has resulted in less
emphasis on expert opinion, yielding a partially validated prob-
abilistic model which can be adapted for numerous health care
settings.
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OBJECTIVES: The utility of quality adjusted life years (QALYs)
as an evaluative tool in clinical psychiatric research and drug
trials relating to schizophrenia has rarely been tested due to the
many limitations surrounding its use. The limitations include
lack of comprehensive models of quality of life speciﬁc to schiz-
ophrenia, unavailability of appropriate measures sensitive
enough to pick up small changes that are expected in the course
of the illness, and lack of adequate information about the per-
formance of available instruments. METHODS: This paper
reviews currently available evidence on the use of QALYs in
studies of people with schizophrenia examining the relationship
